

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Extrawell and/or securities of United Gene.



**EXTRAWELL PHARMACEUTICAL
HOLDINGS LIMITED**

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 858)



**UNITED GENE HIGH-TECH
GROUP LIMITED**

聯合基因科技集團有限公司

*(Incorporated in the Cayman Islands and
continued in Bermuda with limited liability)*

(Stock Code: 399)

**JOINT CLARIFICATION ANNOUNCEMENT
IN RELATION TO**

**MAJOR AND CONNECTED
TRANSACTION CONCERNING
THE DISPOSAL OF
51% SHAREHOLDING INTEREST
IN SMART ASCENT LIMITED**

**(1) MAJOR TRANSACTION;
(2) PROPOSED ISSUANCE OF
CONVERTIBLE BONDS UNDER
THE SPECIFIC MANDATE; AND
(3) CONTINUING CONNECTED
TRANSACTION CONCERNING
THE ACQUISITION OF
51% SHAREHOLDING INTEREST
IN SMART ASCENT LIMITED**

Reference is made to the joint announcement of United Gene and Extrawell dated 18 March 2014 (the “**Announcement**”) in relation to, among other things, the Acquisition and Acquisition Agreement in relation to the Major Transaction; Proposed Issuance of Convertible Bonds under the Specific Mandate; and Continuing Connected Transaction concerning the Acquisition of 51% Shareholding Interest in Smart Ascent Limited by United Gene. Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless otherwise stated.

* *For identification purpose only*

CLARIFICATION

The respective boards of directors of United Gene and Extrawell would like to clarify that the maximum aggregate annual values (proposed annual caps) payable by United Gene Group (the “**Aggregate Annual Caps**”) for the transactions contemplated under the Acquisition for the financial years ending 31 March 2015, 31 March 2016, and 31 March 2017 shall be as follows:

Period	Aggregate Annual Caps <i>HK\$</i> <i>(approximate)</i>
For the year ending 31 March 2015	200,000,000
For the year ending 31 March 2016	500,000,000
For the year ending 31 March 2017	600,000,000

Saved as disclosed herein, all other information and content indicated in the Announcement remain unchanged.

By Order of the Board Extrawell Pharmaceutical Holdings Limited Xie Yi <i>Chairman</i>	By Order of the Board United Gene High-Tech Group Limited Lee Nga Yan <i>Executive Director</i>
---	--

Hong Kong, 19 March 2014

As at the date of this announcement, the board of directors of United Gene comprises Ms. Jiang Nian (chairman & non-executive director), Ms. Lee Nga Yan (executive director), Dr. Guo Yi (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).

As at the date of this announcement, the board of directors of Extrawell comprises executive directors as Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and independent non-executive directors as Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.